1. | Exploration of safe yet efficacious doses of 8-aminoquinolines for the radical cure of vivax malaria and the reduction of falciparum transmission. |
2. | Definition of the relationship between genotype, enzyme activity and co-factors. |
3. | Understanding of the relationship between 8-aminoquinoline dose and risk of haemolysis in G6PD normal and deficient individuals. |
4. | Determining the correlation between enzyme activity and the severity of haemolysis. |
5. | Definition of a threshold of G6PD activity that stakeholders, including regulatory agencies consider sufficient to administer safely standard 8-aminoquinoline regimens. |
6. | Consensus on the degree of haemolysis (i e, proportion of red cell lysis) that constitutes an unacceptable clinical risk to the patient. |
7. | Investigation of the mean level of haemolysis in uncomplicated malaria without primaquine treatment. |
8. | What are acceptable test characteristics (e g, sensitivity and specificity) of rapid tests in various populations and field conditions? |
9. | High resolution mapping of G6PD deficiency and haemolysis risks across major malaria endemic settings. |
10. | Analysis of the cost-effectiveness of G6PD deficiency tests and the risk benefit of deploying or withholding primaquine regimens for P. vivax infections. |